

**Debating the way to lung cancer. The international and Italian viewpoint**

**Milano, 9 marzo 2017**

**Hilton Milan - Via Galvani, 12**

**RATIONAL**

The paradigm of lung cancer therapy has changed greatly over the last few years.

The program aims at sharing with the medical community clinical guidance and thoughts for the management of patients with lung cancer.

Recent advances in tumour genome molecular analysis revealed that dysregulated signals of a number of proto-oncogenes, and of epidermal growth factor receptor (EGFR) in particular, play a key role in profiling lung cancer patients and therefore in performing the most appropriate therapeutic choice.

With these new diagnostic possibilities, new classes of drugs are revolutionizing therapy in lung cancer: immunotherapy, anti-angiogenic therapy and target therapy.

The optimal therapeutic sequence is the one tailored on the medical history of each patient; however, the results coming from clinical trials, clinical practice and guidelines are inescapable resources to be recognized for an evidence-based medicine approach.

Hence the importance of sharing experiences in Italy and at international level.

This event program, gathering together knowledge and expertise of a panel of experts, addresses key issues and current understanding in the diagnosis, staging and treatment of lung cancer by exploring the best patient-centred clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic.

**Debating the way to lung cancer. The international and Italian viewpoint**

**Milano, 9 marzo 2017**

**Hilton Milan - Via Galvani, 12**

**h. 9.00 – 19.00**

**PROGRAMMA SCIENTIFICO**

9.00 – 9.30	Accoglienza e Registrazione	
9.30 – 10.00	Apertura Lavori, introduzione e obiettivi dell'incontro	<i>Diego Cortinovis Vanessa Gregorc</i>
	<b>PRIMA SESSIONE – Moderatore: Alessandra Bearz</b>	
10.00 – 10.30	L'approccio terapeutico e l'esperienza clinica dell'est Europa nei pazienti con NSCLC EGFR mutati	<i>Rafal Dziadziuszko</i>
10.30 – 11.00	Pros & Contra.	<i>Marcello Tiseo</i>
11.00 – 11.30	Discussione plenaria	<i>Moderata A. Bearz</i>
	<b>SECONDA SESSIONE – Moderatore: Mariarita Migliorino</b>	
11.30 – 12.00	L'approccio terapeutico e l'esperienza clinica del nord Europa nei pazienti con NSCLC, adenocarcinoma, wild type	<i>Christian Rolfo</i>
12.00 – 12.30	Pros & Contra.	<i>Diego Cortinovis</i>
12.30 – 13.00	Discussione plenaria	<i>Moderata M. Migliorino</i>
13.00 – 14.00	<b>LUNCH</b>	
	<b>TERZA SESSIONE – Moderatore: TBD</b>	
14.00 – 14.30	Percorso terapeutico nel paziente EGFR mutato	<i>Domenico Galetta</i>
14.30 – 15.00	Percorso terapeutico nel paziente W.T.	<i>Vanessa Gregorc</i>
15.00 – 15.30	Aspetti biomolecolari dei percorsi	<i>Umberto Malapelle</i>
15.30 – 16.00	Discussione plenaria	
16.00 – 16.30	Espressione di accordo	All
	<b>QUARTA SESSIONE – Moderatore: Alessandro Morabito</b>	
16.30 – 18.00	Round table: approccio europeo alla ricerca clinica	
18.00 – 19.00	Conclusioni / Wrap-up and closing remarks	<i>A. Bearz, D. Cortinovis, D. Galetta, V. Gregorc, M. Migliorino, A. Morabito, M. Tiseo, U. Malapelle, C. Rolfo, M. Schuler, R. Dziadziuszko</i>